A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the Knee

NCT ID: NCT04683627

Last Updated: 2025-09-04

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

370 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-29

Study Completion Date

2022-07-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 study to Evaluate the Efficacy and Safety of HP-5000 in Subjects with Osteoarthritis (OA) Pain of the Knee

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-center, randomized, double-blind, and placebo-controlled phase 3 study evaluating the safety and efficacy of HP-5000 in subjects with OA pain of the knees. The study will consist of up to a 28-day Screening Phase that will include a Washout Period of current prescription and over the counter (OTC) analgesics; a 12-week Double-blind Treatment Phase, and a 1-week safety Follow-up Phase.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis Pain of the Knee

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HP-5000 Treatment

HP-5000 Topical Patch will be evaluated against placebo topical patches.

Group Type EXPERIMENTAL

Diclofenac sodium active topical patch

Intervention Type DRUG

A topical patch with diclofenac sodium as active ingredient was used and evaluated for the treatment of OA pain of the knee.

Placebo Treatment

Placebo patches without diclofenac sodium will be used.

Group Type PLACEBO_COMPARATOR

Placebo patch

Intervention Type DRUG

A placebo patch without diclofenac sodium was used for the placebo arm.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diclofenac sodium active topical patch

A topical patch with diclofenac sodium as active ingredient was used and evaluated for the treatment of OA pain of the knee.

Intervention Type DRUG

Placebo patch

A placebo patch without diclofenac sodium was used for the placebo arm.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

HP-5000 Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female aged 40 to 85 years with a clinical diagnosis of OA of the target knee according to the American College of Rheumatology criteria.
* Has an X-ray of the target knee, taken no more than 1 year before Baseline, showing evidence of OA.
* Has pain of OA in the designated/target study knee.

Exclusion Criteria

* Body mass index (BMI) \> 40.
* Any subject who did not follow the restriction of prohibited therapies during Washout period.
* Arthritis of the target knee that is not caused by OA but caused by diseases such as rheumatoid arthritis, gout, psoriasis, syphilitic arthropathy, ochronosis, metabolic or other primary bone disease, or acute traumatic injury.
Minimum Eligible Age

40 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Noven Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Study Director

Role: STUDY_DIRECTOR

Noven Pharmaceuticals, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Applied Research Center of Arkansas

Little Rock, Arkansas, United States

Site Status

Clinical Research of West Florida,Inc.

Clearwater, Florida, United States

Site Status

Universal Axon Clinical Research, LLC

Doral, Florida, United States

Site Status

The Arthritis and Diabetes Clinic, Inc.

Monroe, Louisiana, United States

Site Status

Noven Pharmaceuticals, Inc.

Jersey City, New Jersey, United States

Site Status

Velocity Clinical Research

Cincinnati, Ohio, United States

Site Status

Partners in Clinical Research

Cumberland, Rhode Island, United States

Site Status

Palmetto Clinical Research

Summerville, South Carolina, United States

Site Status

Metroplex Clinical Research Center

Dallas, Texas, United States

Site Status

Quality Research Inc.

San Antonio, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HP-5000-US-07

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.